Acorai Heart Monitor (SAVE Sensor System)
Non-invasive cardiac and pulmonary pressure sensing for heart failure management
Device · EmbeddedCompany source
Company profile
About Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Company description Acorai official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Acorai?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiac decompensation
- Heart failure
- Hemodynamic congestion
Who it serves
- Health Systems
- Healthcare Providers
- Heart Failure Clinics
- Hospitals
Deployment & integration
Embedded deployment with recorded integration context.
Geographic context
MarketsCanada · Europe · Sweden · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Clinically tested in over 2000 patients across 20 hospitals in 6 countries. FDA Breakthrough Device Designation granted. Planning Research Use Only device availability in 2026. Targeting FDA clearance in 2027.
Partnerships
Recorded partners
- Bayer AG
- EIT Health Gold Track
- KHP Ventures (King's College London, King's College Hospital NHS, Guy's and St Thomas' Hospital NHS)
- Life Science Invest
- Saint Luke's Health System
- Västra Götaland Region
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Artificial Intelligence in Cardiovascular Clinical Trials.Journal of the American College of Cardiology · Nov 12, 2024
Current approaches to preventing heart failure readmissions and decompensated disease.Minerva cardiology and angiology · Oct 1, 2024
Clinical validation
Clinical-trial records
A Multi-site, Prospective, Non-interventional, Observational Data Collection Study in Patients Undergoing a Right Heart CatheterizationNCT07010562 · Sponsor · NOT YET RECRUITING
Non-Invasive Hemodynamic Monitoring in Hospitalized Heart FailureNCT07671742 · Sponsor · RECRUITING
A Prospective, Observational, Single Centre Study to Assess the Feasibility of the Data Harvested by the Acorai Intracardiac Pressure Monitoring (ICPM) System in Predicting Prognosis in Patients Discharged From Hospital After Treatment for Acute Decompensated Heart FailureNCT06397833 · Mentioned · RECRUITING
Acorai Machine Learning Generalization (MLG) StudyNCT05835024 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Reduced readmission rates
Ensuring patients are stable prior to discharge
Reduced length of stay
Better understanding of patient stability enables better discharge decisions
Reduced complications
Continuous monitoring improves medication decisions and patient stability
Resource savings
System-wide use would lead to resource savings while improving outcomes
Medical University of South Carolina
Rapid evaluation of patients with suspected heart failure exacerbations
Ability to rapidly and accurately rule out significant congestion
Sinai Health, Toronto
Streamlining daily clinical decisions for heart failure patients in hospital and clinic settings
Non-invasive sensor technology accurately reflects hemodynamic state for daily decision-making
St. Luke's Health System
Heart failure patient management and resource optimization
System-wide use would lead to resource savings while simultaneously improving outcomes for patients with heart failure
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Filip Peters
Co-Founder & CEO
06 · Company updates
Updates from Acorai
Recent articles published on Acorai's official website.
March 25, 2026
Read on AcoraiAcorai Announces First Patient Enrolled in 1,000-Patient HOSP-HF Study
Read on AcoraiAcorai Announces First Patient Enrolled in 1,000-Patient HOSP-HF Study
Read on AcoraiDecember 24, 2025
Read on AcoraiCEO Notes: 2025 Year-in-review and looking forward to 2026
Read on Acorai07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.